The impact of GΑQ signaling on intraocular pressure
Active Project Grant Awarded Last action
- Award ID
- F31EY039120
- Recipient
-
Trustees Of Indiana University UEI SHHBRBAPSM35
- Awarding agency
-
National Eye Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $34,384
Award facts
- Assistance listing
- 93.867 Vision Research
- Completion date 0% complete
- Place of performance
- Indianapolis, IN 46202, USA
Award details come from USAspending.gov.
Description
- Abstract
- Primary open-angle glaucoma (poag) is the most common form of glaucoma and a leading cause of irreversible blindness worldwide. Elevated intraocular pressure (IOP), the most significant modifiable and clinically approved risk factor for poag, results from impaired aqueous humor drainage through the trabecular meshwork (TM), a tissue that becomes stiffened due to increased actin polymerization and extracellular matrix (ECM) remodeling. While current IOP-lowering treatments exist, they are often accompanied by adverse side effects and fail to address the underlying biomechanical dysfunction of the TM, highlighting the need for safer and more targeted therapies. This project investigates the role of GΑQ signaling, and its upstream mediator endothelin-1 (ET-1), in promoting actin-based contractility and ECM remodeling in the TM, contributing to increased IOP. Preliminary studies suggest that pharmacologic inhibitors of GΑQ, YM-254890 and FR900359, reduce actin polymerization and lower IOP, identifying GΑQ as a promising therapeutic target. The central hypothesis is that the pharmacological inactivation of GΑQ can prevent IOP elevation by reducing the ET signaling via ET receptors, thus preventing blindness in glaucoma. Aim 1 will assess the impact of GΑQ inhibition on TM biomechanics and IOP in vivo. Aim 2 will investigate the role of GΑQ-mediated signaling in ET- 1-induced IOP elevation and glaucoma. By elucidating the mechanistic role of GΑQ and ET-1 signaling in TM dysfunction, this work may lead to the development of novel, mechanism-based therapies to optimize treatment for poag in patients and reduce the global burden of glaucoma.
Quick answers
Who received award F31EY039120?
F31EY039120 was awarded to Trustees Of Indiana University by National Eye Institute (National Institutes of Health) on March 2, 2027.
How much is award F31EY039120 worth?
$34,384 has been obligated on F31EY039120.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award